Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
Data Hub
Contact
Privacy PolicyFinal MICROB-PREDICT General Assembly & 6th Masterclass
From 28–30 September 2026, the MICROB-PREDICT consortium will come together in Barcelona (Bellaterra), Spain, for its 8th and Final General Assembly (GA) Meeting, marking the culmination of seven years of collaborative research. The meeting will focus on the project’s key scientific achievements, work package results and project closure, remaining publications, dissemination, impact, and legacy. We will also discuss the ALB-TRIAL, biomarker and biosensor development, post-project access to data, samples, and software, ownership, and protection and exploitation of project results. The GA will conclude with an exciting MICROB-PREDICT Masterclass, featuring an open-format creative Science Slam, lessons learned from the Delphi “Oracle”, a session on Scientific Conference Planning, as well as ICN2’s vision and technologies, especially its Nanobioelectronics and Biosensors. Before the goodbye lunch, we will have the opportunity to tour the ICN2 laboratories and building!
More newsMICROB-PREDICT Results Videos: Sharing our innovation with scientists and liver patients
As the project approaches the finish line (September 2026), MICROB-PREDICT has launched a comprehensive 17-part results video series to showcase its scientific achievements and maximise the project's long-term impact. The collection includes eight Expert Presentations highlighting key discoveries on biomarkers, microbiome research, multi-omics, gut barrier dysfunction, metabolomics and novel therapeutic targets for cirrhosis and ACLF, alongside nine Easy Results Videos that translate these advances for patients and the general public - featuring ELPA president Marko Korenjak as interviewer. Together, these video series help bridge the gap between research, clinical practice, and patient understanding, ensuring that MICROB-PREDICT's discoveries continue to inform both future liver disease research and improved care for patients.
More newsMICROB-PREDICT project video
Focus on human microbiome to fight liver cirrhosis: 22 European institutions joined forces in January 2019 to improve the prevention and treatment of chronic liver disease (cirrhosis) within the MICROB-PREDICT project. We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis) and decompensated cirrhosis progresses to acute-on-chronic liver failure (ACLF), and individual treatment responses of patients. Coordinator Jonel Trebicka gives a brief overview of the project in this video.
More news